Sofinnova Ventures Inc Buys Inozyme Pharma Inc, Amgen Inc, NuCana PLC, Sells Principia Biopharma Inc, Gilead Sciences Inc, Amarin Corp PLC

• New Purchases: INZY, AMGN, ATHA, GWPH, OVID, TCRR, ACAD, FATE, RGNX, SVRA,
• Added Positions: NCNA, BMRN, ABBV, ITCI, ARNA, RETA, KRTX, INSM, CYTK, OTIC, UTHR, CGEN, PTGX,
• Reduced Positions: AMRN, CHRS, MRK, XLRN, KNSA, JAZZ, TGTX, PBYI, KURA, MYOK, ZYME, KDMN, MIRM, SUPN, CHMA, CALA, BCRX, AGTC, PTCT, FIXX, LLY, LQDA, CCXI, ETTX,
• Sold Out: PRNB, GILD, HZNP, AKBA, BPMC, AXSM, CNST, KALA, MRSN, APLS, SNDX, NTLA, IMVT, MRTX, ORIC, RIGL,

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolio

1. Natera Inc (NTRA) - 3,100,560 shares, 18.38% of the total portfolio.
2. Ascendis Pharma A/S (ASND) - 1,109,874 shares, 14.05% of the total portfolio.
3. Karuna Therapeutics Inc (KRTX) - 1,952,441 shares, 12.39% of the total portfolio. Shares added by 3.54%
4. Y-mAbs Therapeutics Inc (YMAB) - 2,194,278 shares, 6.91% of the total portfolio.
5. Inozyme Pharma Inc (INZY) - 2,028,308 shares, 4.38% of the total portfolio. New Position

Sofinnova Ventures Inc initiated holding in Inozyme Pharma Inc. The purchase prices were between $17.54 and $30.2, with an estimated average price of $24.9. The stock is now traded at around $24.66. The impact to a portfolio due to this purchase was 4.38%. The holding were 2,028,308 shares as of .

Sofinnova Ventures Inc initiated holding in Amgen Inc. The purchase prices were between $234.65 and $260.95, with an estimated average price of $247.91. The stock is now traded at around $237.36. The impact to a portfolio due to this purchase was 2.33%. The holding were 111,619 shares as of .

Sofinnova Ventures Inc initiated holding in Athira Pharma Inc. The purchase prices were between $16.02 and $18.46, with an estimated average price of $16.7. The stock is now traded at around $26.50. The impact to a portfolio due to this purchase was 0.77%. The holding were 509,168 shares as of .

Sofinnova Ventures Inc initiated holding in GW Pharmaceuticals PLC. The purchase prices were between $97.35 and $139.54, with an estimated average price of $115.01. The stock is now traded at around $118.80. The impact to a portfolio due to this purchase was 0.66%. The holding were 82,944 shares as of .

Sofinnova Ventures Inc initiated holding in Ovid Therapeutics Inc. The purchase prices were between $5.39 and $8.24, with an estimated average price of $6.68. The stock is now traded at around $6.04. The impact to a portfolio due to this purchase was 0.52%. The holding were 1,097,621 shares as of .

Sofinnova Ventures Inc initiated holding in TCR2 Therapeutics Inc. The purchase prices were between $13.1 and $20.69, with an estimated average price of $17.53. The stock is now traded at around $26.93. The impact to a portfolio due to this purchase was 0.29%. The holding were 173,028 shares as of .

Sofinnova Ventures Inc added to a holding in NuCana PLC by 147.06%. The purchase prices were between $4.57 and $6.48, with an estimated average price of $5.42. The stock is now traded at around $4.73. The impact to a portfolio due to this purchase was 1.42%. The holding were 5,599,999 shares as of .

Sofinnova Ventures Inc added to a holding in Biomarin Pharmaceutical Inc by 311.23%. The purchase prices were between $71.87 and $131.03, with an estimated average price of $101.18. The stock is now traded at around $77.52. The impact to a portfolio due to this purchase was 1.22%. The holding were 258,653 shares as of .

Sofinnova Ventures Inc added to a holding in AbbVie Inc by 35.47%. The purchase prices were between $85.91 and $100.83, with an estimated average price of $94.18. The stock is now traded at around $99.04. The impact to a portfolio due to this purchase was 0.64%. The holding were 341,340 shares as of .

Sofinnova Ventures Inc added to a holding in Intra-Cellular Therapies Inc by 108.16%. The purchase prices were between $17.61 and $31.86, with an estimated average price of $22.76. The stock is now traded at around $26.77. The impact to a portfolio due to this purchase was 0.55%. The holding were 503,555 shares as of .

Sofinnova Ventures Inc added to a holding in Reata Pharmaceuticals Inc by 426.39%. The purchase prices were between $93.53 and $163.34, with an estimated average price of $125.03. The stock is now traded at around $175.58. The impact to a portfolio due to this purchase was 0.45%. The holding were 68,615 shares as of .

Sofinnova Ventures Inc added to a holding in Arena Pharmaceuticals Inc by 532.85%. The purchase prices were between $60.76 and $75.83, with an estimated average price of $66.59. The stock is now traded at around $66.68. The impact to a portfolio due to this purchase was 0.45%. The holding were 88,150 shares as of .

Sofinnova Ventures Inc sold out a holding in Principia Biopharma Inc. The sale prices were between $56 and $101.07, with an estimated average price of $88.57.

Sofinnova Ventures Inc sold out a holding in Gilead Sciences Inc. The sale prices were between $62.1 and $78.08, with an estimated average price of $69.4.

Sofinnova Ventures Inc sold out a holding in Horizon Therapeutics PLC. The sale prices were between $55.23 and $79.93, with an estimated average price of $68.64.

Sofinnova Ventures Inc sold out a holding in Akebia Therapeutics Inc. The sale prices were between $2.39 and $13.08, with an estimated average price of $8.75.

Sofinnova Ventures Inc sold out a holding in Blueprint Medicines Corp. The sale prices were between $66.45 and $92.7, with an estimated average price of $76.98.

Sofinnova Ventures Inc sold out a holding in Axsome Therapeutics Inc. The sale prices were between $68.34 and $85.84, with an estimated average price of $77.82.